A conversation on the rising trends in the cardiology space
Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.
During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.
Episode topics include:
- Why pharma’s interest in specialty-like approaches has shifted towards cardiology
- The promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)
- How these newer treatments stack up against traditional small molecule orals, like statins
- Clinical stage pipeline analysis across cardiology and visible trends on the horizon
This is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch:
www.bblsa.comWhat is Back Bay Life Science Report?
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.